Press release
KalVista Pharmaceuticals Presents Real-World Data at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
– Patient perspectives on challenges with currently available parenteral on-demand HAE treatments explain basis for non-compliance with treatment guidelines
About this update from Kalvista Pharmaceuticals, Inc.
[{"type":"text","content":"\n– Patient perspectives on challenges with currently available parenteral on-demand HAE treatments explain basis for non-compliance with treatment guidelines –\n\n\n– Global prevalence of normal C1-inhibitor HAE (HAE-nC1-INH) may be greater than previously realized –\n\n\n CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--\nKalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data on anxiety associated with the use of injectable on-demand treatments for hereditary angioedema (HAE) attacks and patient perspectives on why people living with HAE don’t often carry their on-demand treatment outside the home at the 2023 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Anaheim, CA.\n\n\n“We continue to learn from people living with HAE that currently available parenteral on-demand treatments are simply not meeting their needs,” said Andrew Crockett, Chief Executive Officer of KalVista. “Whether this is related to always carrying their syringes or vials, challenges in preparing and administering injectable or infused treatments outside the home, or anxiety related to potential injection-site reactions and pain, patients struggle to follow treatment guidelines. This can lead to non-compliance and preference for long-term prophylaxis, even in cases where on-demand treatments would otherwise suffice. We also note that despite the use of long-term prophylaxis, HAE patients require HAE-related home health visits and seek ER treatment more often than would be expected. It is our hope that if sebetralstat is approved for the on-demand treatment of HAE, it may be able to address this significant unmet need and help transform the management of the disease.”\n\n\nIn addition to the data on persisting non-medication health resource utilization among patients receiving long-term prophylaxis, the Company presented data on the global prevalence of HAE-nC1-INH the approach to the presumptive diagnosis, and the highly varied treatment approaches that represent another significant area of unmet need in that population.\n\n\nThe following presentations occurred at ACAAI 2023:\n\n\n\nAnxiety Associated with On-Demand Treatm...